OBJECTIVE: To evaluate a new chemiluminescent microparticle immunoassay (ARCHITECT Chagas(®), Abbott). METHODS: In this study, 165 samples were tested by two different serological tests. The ARCHITECT Chagas(®) assay was performed using ARCHITECT i2000(SR) system (Abbott). RESULTS: The sensitivity and specificity of ARCHITECT assay was 100% and 96.6%, respectively. The concordance rate was 0.96 (95%CI: 0.92-1) for ELISA and 0.91 (95%CI: 0.85-0.97) for immunofluorescence assay (IFA). CONCLUSIONS: The ARCHITECT Chagas(®) assay demonstrates a sensitivity and specificity similar to ELISA and IFA assays; it allows a large volume of samples to be processed with a good standardization and reproducibility, as well as an objective interpretation.
OBJECTIVE: To evaluate a new chemiluminescent microparticle immunoassay (ARCHITECT Chagas(®), Abbott). METHODS: In this study, 165 samples were tested by two different serological tests. The ARCHITECT Chagas(®) assay was performed using ARCHITECT i2000(SR) system (Abbott). RESULTS: The sensitivity and specificity of ARCHITECT assay was 100% and 96.6%, respectively. The concordance rate was 0.96 (95%CI: 0.92-1) for ELISA and 0.91 (95%CI: 0.85-0.97) for immunofluorescence assay (IFA). CONCLUSIONS: The ARCHITECT Chagas(®) assay demonstrates a sensitivity and specificity similar to ELISA and IFA assays; it allows a large volume of samples to be processed with a good standardization and reproducibility, as well as an objective interpretation.
Authors: Jeel Moya-Salazar; Roberto Ubidia-Incio; Maritza Incio-Grande; Jorgelina L Blejer; Carlos A Gonzalez Journal: Rev Bras Hematol Hemoter Date: 2017-01-23